A Pilot Study on the Efficacy and Safety of Olanzapine in Gastroparesis
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01625923|
Recruitment Status : Recruiting
First Posted : June 22, 2012
Last Update Posted : July 2, 2017
|Condition or disease||Intervention/treatment|
|Idiopathic Gastroparesis||Drug: Olanzapine|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||20 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||A Pilot Study on the Efficacy and Safety of Olanzapine in Improving Symptoms and Gastric Motility in Gastroparesis|
|Study Start Date :||January 2013|
|Estimated Primary Completion Date :||December 2018|
|Estimated Study Completion Date :||December 2018|
An open-label pilot study of 20 consecutive subjects ages 18 - 70 with documented delayed gastric emptying within the past 2 years and history of nausea, vomiting, bloating, anorexia, early satiation, post-prandial fullness, and weight loss for at least 6 months without structural or organic cause will be enrolled.
Subjects will initially start on olanzapine 2.5 mg per mouth daily. Subjects will return on days 7 and 14 to determine response to medication and medication dose can be increased to 5 mg and 10 mg, respectively, based on incomplete symptom response (mean change GCSI-DD < 0.5). The total dose of olanzapine will not exceed 10 mg daily during this study and subjects will continue on treatment for a total of 8 weeks.
Other Name: Zyprexa
- Number of subjects with adverse events [ Time Frame: 8 weeks ]Subjects will undergo regular testing of blood glucose, insulin, hemoglobin (Hgb) A1c, body mass index (BMI), liver enzymes, thyroid stimulating hormone (TSH), and prolactin levels during the study as well as after treatment completion to determine the safety of the medication. All adverse events will be compiled to investigate the tolerability of the medication.
- Number of subjects with symptomatic improvement [ Time Frame: 8 weeks ]The investigators will utilize the gastroparesis cardinal symptom index daily diary (GCSI-DD) and an appetite visual analog scale (VAS) to compare severity of symptoms before and after treatment with olanzapine.
- Number of subjects with improved gastric motility [ Time Frame: 8 weeks ]The investigators aim to test gastric motility, including gastric emptying and antroduodenal contractility parameters, by wireless motility capsule (WMC) before and at the completion of the study to determine if olanzapine has any pro-motility effects in gastroparesis.
- Number of subjects with altered ghrelin levels [ Time Frame: 8 weeks ]The investigators seek to determine whether olanzapine promotes secretion of ghrelin in gastroparesis.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01625923
|Contact: Allen Lee, MD||(734) 936-9454|
|Contact: William Hasler, MD|
|United States, Massachusetts|
|Massachusetts General Hospital||Recruiting|
|Boston, Massachusetts, United States, 02114|
|Contact: Braden Kuo, MD 617-726-0196|
|Principal Investigator: Braden Kuo, MD|
|United States, Michigan|
|University of Michigan||Recruiting|
|Ann Arbor, Michigan, United States, 48109|
|Contact: Allen Lee, MD 734-936-9454|
|Principal Investigator: Allen Lee, MD|
|Sub-Investigator: William Hasler, MD|
|Principal Investigator:||Allen Lee, MD||University of Michigan|
|Principal Investigator:||Braden Kuo, MD||Massachusetts General Hospital|
|Principal Investigator:||William Hasler, MD||University of Michigan|